Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
New draft guidelines on the definition of new active substances don’t apply to deutetrabenazine, the European drug regulator ...
At exposure levels associated with its clinical dose of 150 mg once daily, GLPG3667 showed inhibition of the IFN-α, and IL-23 pathways, comparable to the expected inhibition for the currently approved ...
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...
Medpage Today on MSN
Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial
Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...
EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...
Unleash the joy! Shop our picks of must-have gifts for pet owners, from dogs and cats to rabbits, to make sure your fur-baby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback